DSW Reaches New 52-Week High (DSW)

NEW YORK ( TheStreet) -- DSW (NYSE: DSW) hit a new 52-week high Monday as it is currently trading at $79.13, above its previous 52-week high of $77.50 with 154,988 shares traded as of 10:40 a.m. ET. Average volume has been 431,200 shares over the past 30 days.

DSW has a market cap of $2.76 billion and is part of the services sector and retail industry. Shares are up 17.2% year to date as of the close of trading on Friday.

DSW Inc. operates as a branded footwear and accessories specialty retailer in the United States. The company offers fashion, shoes, dress, casual and athletic footwear, and accessories for women and men through its DSW stores and dsw.com.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates DSW as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full DSW Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..

null

More from Markets

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI